tirzepatide surmount 2 ECO 2026: SURMOUNT-MAINTAIN proves sustains weight loss long term PDF) Tirzepatide for the treatment

Wegovy is a GLP-1 receptor agonist licensed for chronic weight management, whilst Topamax is an antiepileptic drug indicated for epilepsy and migraine prophylaxis

These check-ins allow your doctor to assess your response to the therapy by measuring key biomarkers like IGF-1, glucose, and thyroid levels

Tirzepatide after intensive lifestyle intervention (SURMOUNT-3)

J Pharm Pract 2009;22:540-545.ArticlePDF 47

Clinical research indicates that adults can lose between 15 to 20 percent of their body weight when semaglutide is paired with lifestyle adjustments, standing out as a leading weight loss solution

For most patients, its out with compounded GLP-1s for weight loss and in with discounted branded drugs